Embera NeuroTherapeutics, Inc. Closes Series A Funding, Starting FDA Trial Process

Embera NeuroTherapeutics, Inc., a start-up company developing novel treatments for a broad range of addictions, as well as other neuropsychiatric disorders, has secured over $800,000 of Series A financing that will help the company move its novel combinational drug into Phase 1b FDA trials. (PRWeb Feb 8, 2007) Post Comment:Trackback URL: ...
From: prweb.com